Cargando…

Long-Acting Buprenorphine Formulations as a New Strategy for the Treatment of Opioid Use Disorder

Long-acting buprenorphine formulations have been recently marketed for the Opioid Agonist Treatment (OAT) of opioid use disorder (OUD) associated with medical, social, and psychological support. Their duration of action ranges from one week up to 6 months. The non-medical use of opioids is increasin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maremmani, Icro, Dematteis, Maurice, Gorzelanczyk, Edward J., Mugelli, Alessandro, Walcher, Stephan, Torrens, Marta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10488107/ https://www.ncbi.nlm.nih.gov/pubmed/37685642 http://dx.doi.org/10.3390/jcm12175575

Ejemplares similares

Recent advances in the treatment of opioid use disorders–focus on long-acting buprenorphine formulations
por: Soyka, Michael, et al.
Publicado: (2021)

What we have learned from the Methadone Maintenance Treatment of Dual Disorder Heroin Use Disorder patients
por: Maremmani, Angelo G.I., et al.
Publicado: (2019)

Do methadone and buprenorphine have the same impact on psychopathological symptoms of heroin addicts?
por: Maremmani, Angelo Giovanni Icro, et al.
Publicado: (2011)

Psychomotor Symptoms in Chronic Cocaine Users: An Interpretative Model
por: Cenci, Davide, et al.
Publicado: (2022)

A Call to Action: Integration of Buprenorphine Prescribing Into the Care of Persons With Human Immunodeficiency Virus and Opioid Use Disorder
por: Fujita, A Wendy, et al.
Publicado: (2022)

Managing opioid withdrawal precipitated by buprenorphine with buprenorphine
por: Oakley, Bridget, et al.
Publicado: (2021)

Non-Medical Use of Novel Synthetic Opioids: A New Challenge to Public Health
por: Lovrecic, Barbara, et al.
Publicado: (2019)

The newer Opioid Agonist Treatment with lower substitutive opiate doses is associated with better toxicology outcome than the older Harm Reduction Treatment
por: Bizzarri, Jacopo V., et al.
Publicado: (2016)

Comparison of Buprenorphine and Buprenorphine/naloxone in Detoxification of Opioid-dependent Men
por: Ziaaddini, Hassan, et al.
Publicado: (2018)

Erratum to: Agonist Opioid Treatment as historical comprehensive treatment (‘Dole & Nyswander’ methodology) is associated with better toxicology outcome than Harm Reduction Treatment
por: Bizzarri, Jacopo V., et al.
Publicado: (2017)

Adult-Attention Deficit Hyperactive Disorder Symptoms Seem Not to Influence the Outcome of an Enhanced Agonist Opioid Treatment: A 30-Year Follow-Up
por: Maremmani, Angelo G. I., et al.
Publicado: (2021)

Characteristics of Stress Sensitivity in Heroin Use Disorder Patients during Their Opioid Agonist Treatment
por: Della Rocca, Filippo, et al.
Publicado: (2023)

Long-Term γ-Hydroxybutyric Acid (GHB) and Disulfiram Combination Therapy in GHB Treatment-Resistant Chronic Alcoholics
por: Maremmani, Angelo Giovanni Icro, et al.
Publicado: (2011)

Advances in the delivery of buprenorphine for opioid dependence
por: Rosenthal, Richard N, et al.
Publicado: (2017)

Role of Buprenorphine in an Adolescent with Opioid Abuse
por: Weesner, Elizabeth, et al.
Publicado: (2022)

Buprenorphine‐naloxone, buprenorphine, and methadone throughout pregnancy in maternal opioid use disorder
por: Kanervo, Minna M., et al.
Publicado: (2022)

Psychopathological symptoms of patients with heroin addiction entering opioid agonist or therapeutic community treatment
por: Pani, Pier Paolo, et al.
Publicado: (2014)

Changes in Buprenorphine-Naloxone and Opioid Pain Reliever Prescriptions After the Affordable Care Act Medicaid Expansion
por: Saloner, Brendan, et al.
Publicado: (2018)

Prevalence and Characteristics of Chronic Pain in Buprenorphine and Methadone-Maintained Patients
por: Delorme, Jessica, et al.
Publicado: (2021)

Treatment of opioid dependence with buprenorphine: current update
por: Soyka, Michael
Publicado: (2017)

The Pharmacology of Buprenorphine Microinduction for Opioid Use Disorder
por: De Aquino, Joao P., et al.
Publicado: (2021)

Management of Opioid Addiction With Opioid Substitution Treatments: Beyond Methadone and Buprenorphine
por: Noble, Florence, et al.
Publicado: (2019)

The long-term outcome of patients with heroin use disorder/dual disorder (chronic psychosis) after admission to enhanced methadone maintenance
por: Maremmani, Angelo G. I., et al.
Publicado: (2018)

Buprenorphine initiation strategies for opioid use disorder and pain management: A systematic review
por: Spreen, Lauren A., et al.
Publicado: (2022)

Patients Maintained on Buprenorphine for Opioid Use Disorder Should Continue Buprenorphine Through the Perioperative Period
por: Lembke, Anna, et al.
Publicado: (2019)

Evaluating buprenorphine prescribing and opioid-related health outcomes following the expansion the buprenorphine waiver program
por: Rowe, Christopher L., et al.
Publicado: (2022)

Patients’ goals when initiating long-acting injectable buprenorphine treatment for opioid use disorder: findings from a longitudinal qualitative study
por: Neale, Joanne, et al.
Publicado: (2023)

The Conceptual Framework of Dual Disorders and Its Flaws
por: Pacini, Matteo, et al.
Publicado: (2020)

Use of a Long-Acting Opioid Microsphere Formulation to Overcome Difficulties in Swallowing Pain Medication
por: Anderson, Nathan, et al.
Publicado: (2020)

Pattern of buprenorphine abuse among opioid abusers in Nepal
por: Aich, Tapas Kumar, et al.
Publicado: (2010)

Comparison of the Efficacy of Buprenorphine and Clonidine in Detoxification of Opioid-Dependents
por: Ziaaddini, Hassan, et al.
Publicado: (2012)

Sleep problems in opioid dependent patients maintained on buprenorphine
por: Tripathi, R., et al.
Publicado: (2021)

Personalized Care in Opioid Use Disorder maintained on Buprenorphine
por: Elarabi, H., et al.
Publicado: (2022)

Inpatient Buprenorphine Induction for Opioid Use Disorder in Pregnancy
por: Tavakoli, Amin, et al.
Publicado: (2023)

A urinalysis-based study of buprenorphine and non-prescription opioid use among patients on buprenorphine maintenance
por: Balhara, Yatan Pal Singh, et al.
Publicado: (2012)

Association of Buprenorphine-Waivered Physician Supply With Buprenorphine Treatment Use and Prescription Opioid Use in Medicaid Enrollees
por: Wen, Hefei, et al.
Publicado: (2018)

Buprenorphine Dosage and Urine Quantitative Buprenorphine, Norbuprenorphine, and Creatinine Levels in an Office-Based Opioid Treatment Program
por: Furo, Hiroko, et al.
Publicado: (2021)

Can Ropinirole Modulate Reinforcing Subjective Effects of Cocaine in Humans?
por: Maremmani, Angelo Giovanni Icro, et al.
Publicado: (2011)

Successful outcomes using Long Acting Buprenorphine (LAB - Buvidal) to treat Codeine, Tramadol and other Opioid Analgesia Dependencies (OAD) in Wales during the Pandemic
por: Melichar, J., et al.
Publicado: (2022)

A call to maximize impact of the SUPPORT for Patients and Communities Act through standard inclusion of opioid use disorder treatment curricula in medical schools
por: Shapiro, Aaron, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_8c6bioh3jc1593ptn6dinbjue8